Browse News
Filter News
Found 433 articles
-
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
4/22/2024
Guardant Health, Inc. today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled to review the premarket approval (PMA) application for the company’s Shield™ blood test for colorectal cancer (CRC) screening on Thursday, May 23, 2024.
-
Liquid Biopsy Industry is Rising Rapidly Up to USD 32.54 Bn by 2033
4/19/2024
The global liquid biopsy market size was valued at USD 10.85 billion in 2023 and is projected to reach USD 32.54 billion by 2033, growing at a CAGR of 11.61% from 2024 to 2033 according to a new report by Nova One Advisor.
-
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
4/7/2024
Black Diamond Therapeutics, Inc. presented real-world evidence of the evolving epidermal growth factor receptor mutation landscape in non-small cell lung cancer, and the potential of BDTX-1535 to address a broader range of mutations compared to existing therapies.
-
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
4/3/2024
Guardant Health, Inc. today announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego.
-
Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC
3/19/2024
Portal Biotechnologies, Inc., a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.
-
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
3/13/2024
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that results from the ECLIPSE study showing the effectiveness of its ShieldTM blood test for detecting colorectal cancer (CRC) in average-risk adults will be published in the March 14 issue of The New England Journal of Medicine.
-
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 06, 2024
3/6/2024
Guardant Health, Inc. announced that on February 15, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units representing 218,236 shares of its common stock to 82 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 29,048 shares of its common stock to one new non-executive employee with a grant date of February 26, 2024 under the Guardant Health, Inc.
-
BostonGene Bolsters Leadership Team to Accelerate Innovation and Growth
2/22/2024
BostonGene Appoints Joe Lennerz, MD, PhD, as Chief Scientific Officer, Mark Hiatt, MD, MBA, MS as Senior Vice President of Market Access and Strategy and Ned Segal as Board Member.
-
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
2/22/2024
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023.
-
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
2/1/2024
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, February 22, 2024.
-
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
1/17/2024
Guardant Health, Inc. will present interim data from the COSMOS study supporting the use of Guardant Reveal to predict disease recurrence in patients with early-stage colon cancer at the ASCO 2024 Gastrointestinal Cancers Symposium, January 18-20 in San Francisco.
-
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
1/8/2024
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results.
-
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
1/8/2024
Guardant Health, Inc. and Hikma Pharmaceuticals PLC announced an agreement to promote Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across all solid cancers in countries across the Middle East and North Africa.
-
Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer
1/2/2024
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of Terilyn Juarez Monroe as the company’s chief people officer, effective immediately.
-
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
12/21/2023
Guardant Health, Inc., a leading precision oncology company, announced that it has entered into a common stock purchase agreement with Baillie Gifford on behalf of accounts that it manages for the sale of 3,387,446 shares of its common stock in a registered direct offering at an offering price of $26.77 per share.
-
Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
12/20/2023
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.
-
Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
12/19/2023
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket approval application (PMA) for the company’s Shield™ blood test to screen for colorectal cancer on March 28, 2024.
-
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
12/4/2023
Cancer Research UK, one of the world’s largest charitable funders of cancer research, its innovation unit, Cancer Research Horizons, and Guardant Health, Inc., a leading precision oncology company, announced a collaboration to explore the sharing of technologies, data, and insights to advance the development and precision of cancer detection and treatment.
-
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
11/30/2023
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present data showing the utility of liquid biopsy tests in the management of breast cancer patients at the San Antonio Breast Cancer Symposium, December 5-9 in San Antonio, Texas.
-
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 15, 2023
11/15/2023
Guardant Health, Inc., a leading precision oncology company, announced that on November 8, 2023, the Compensation Committee of Guardant’s Board of Directors granted restricted stock units representing 50,741 shares of its common stock to 43 new non-executive employees under the Guardant Health, Inc.